In the Phase 2 trial protocol, participants reached the 12mg maximum dose at week 20 after five escalation steps (1mg, 2mg, 4mg, 8mg, 12mg), each held for four weeks
8 Currently, there are no approved oral formulations of a GLP-1 medicine for weight loss
Presented for research literature review only Vakkuri O et al
Sharps Disposal The needles used for injections must never be thrown directly into the regular trash
1,2 Initially developed as antidiabetic treatments, GLP-1 RAs and, more recently, dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have demonstrated favourable metabolic outcomes with significant and sustainable weight loss in large randomised controlled trials (RCTs) and real-world studies
The number of first occurrences and total individual events contributing to the primary composite endpoint is shown in Table 7